Tag: Oncodesign
Oncodesign receives 745,000 euros from the Deep Tech development aid fund – 01/03/2024 at 10:12
(AOF) – Oncodesign Precision Medicine has received notification of financial assistance from the DeepTech development assistance fund. The biotech specializing in precision medicine for the treatment of resistant and metastatic…
Oncodesign: increase in its capital of around 2 million euros
(AOF) – Oncodesign, a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the result of its capital increase with priority period for shareholders…
Oncodesign Precision Medicine announces the result of its capital increase of approximately €2 million – 02/12/2024 at 08:00
To receive information from ONCODESIGN PRECISION MEDICINE (OPM) in real time, send a request to [email protected] Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a biopharmaceutical company specializing in precision…
Oncodesign wants to raise 3 ME at 1.32 Euro per share
By Arnaud Bivès Published on 01/25/2024 at 8:51 a.m. (Boursier.com) — Oncodesign launches a capital increase with elimination…
Oncodesign secures bank financing of 6 million euros
(AOF) – OPM (Oncodesign Precision Medicine) announces the conclusion of a financing agreement for an amount of 6 million euros granted by three regional banks: Caisse d’Épargne Bourgogne Franche Comté,…
Oncodesign Precision Medicine announces bank financing of 6 million euros granted by Caisse d’Épargne Bourgogne Franche Comté, Crédit Agricole de Champagne Bourgogne and Société Générale – 05/10/2023 at 6:00 p.m.
• This non-dilutive financing allows OPM to continue the clinical development of OPM-101 and support the development of its product portfolio and technologies • This agreement, strategic and unique, highlights:…
Oncodesign secures bank financing of 6 million euros – 05/10/2023 at 6:31 p.m.
(AOF) – OPM (Oncodesign Precision Medicine) announces the conclusion of a financing agreement for an amount of 6 million euros granted by three regional banks: Caisse d’Épargne Bourgogne Franche Comté,…
Oncodesign Precision Medicine: cash of 134 million euros, visibility for the year 2023 – 04/14/2023 at 10:49
(AOF) – Oncodesign Precision Medicine (OPM) announces a cash position of 134 million euros as of December 31, 2022, which ensures its development “for the year to come”, and a…
Oncodesign Precision Medicine will publish its annual results on April 13, 2023 – 03/13/2023 at 18:00
Dijon (France), March 13, 2023 at 6:00 p.m. CET– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and…
Oncodesign: launch of a clinical trial in IBD
(CercleFinance.com) – Oncodesign announced yesterday evening the entry into clinical development of its second drug candidate, with the dosage of a first patient as part of a Phase 1 trial.…
Oncodesign Precision Medicine announces the entry into Phase I of its RIPK2 inhibitor ODS-101, a new therapeutic agent for IBD – 02/09/2023 at 18:00
To receive information from ONCODESIGN PRECISION MEDICINE (OPM) in real time, send a request to [email protected] >> First administration in humans of ODS-101 on healthy volunteers Oncodesign Precision Medicine (OPM)…
Oncodesign PM: fundraising, transfer to Euronext Growth
(CercleFinance.com) – Oncodesign Precision Medicine (OPM) announces the launch of a capital increase with cancellation of preferential subscription rights for an amount of around eight million euros, with a priority…